Vertical Group

MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating neurological disorders. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation to address conditions such as tinnitus, chronic pain, and rehabilitation following strokes. Its flagship product, Vivistim, has received FDA approval for use in ischemic stroke survivors experiencing moderate to severe upper limb impairment. MicroTransponder's innovative approaches, which include paired vagus nerve stimulation and wireless neurostimulation systems, are designed to enhance recovery and improve quality of life for patients facing various neurological challenges.

Route 92 Medical is a medical device company founded in 2015 and based in San Mateo, California. The company specializes in developing innovative solutions for stroke treatment, focusing on a stealthy catheter designed for acute ischemic stroke. Their technology includes a percutaneous catheter, a rapid aspiration thrombectomy system, and an intra-cerebral implant delivery mechanism. These advancements aim to assist healthcare professionals in effectively treating stroke patients and enhancing their recovery outcomes.

Route 92 Medical is a medical device company founded in 2015 and based in San Mateo, California. The company specializes in developing innovative solutions for stroke treatment, focusing on a stealthy catheter designed for acute ischemic stroke. Their technology includes a percutaneous catheter, a rapid aspiration thrombectomy system, and an intra-cerebral implant delivery mechanism. These advancements aim to assist healthcare professionals in effectively treating stroke patients and enhancing their recovery outcomes.

Luminopia is focused on developing innovative treatments for significant neuro-visual disorders, particularly amblyopia, commonly known as lazy eye, which is a leading cause of vision loss in children. The company is creating digital therapeutics that undergo rigorous evaluation for FDA approval while ensuring they are engaging for patients. In collaboration with Boston Children's Hospital, Luminopia is advancing its primary product, Luminopia One, which utilizes a binocular therapeutic approach to effectively address amblyopia. This development aims to enhance the capabilities of healthcare professionals in treating these critical vision disorders.

Luminopia is focused on developing innovative treatments for significant neuro-visual disorders, particularly amblyopia, commonly known as lazy eye, which is a leading cause of vision loss in children. The company is creating digital therapeutics that undergo rigorous evaluation for FDA approval while ensuring they are engaging for patients. In collaboration with Boston Children's Hospital, Luminopia is advancing its primary product, Luminopia One, which utilizes a binocular therapeutic approach to effectively address amblyopia. This development aims to enhance the capabilities of healthcare professionals in treating these critical vision disorders.

MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating neurological disorders. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation to address conditions such as tinnitus, chronic pain, and rehabilitation following strokes. Its flagship product, Vivistim, has received FDA approval for use in ischemic stroke survivors experiencing moderate to severe upper limb impairment. MicroTransponder's innovative approaches, which include paired vagus nerve stimulation and wireless neurostimulation systems, are designed to enhance recovery and improve quality of life for patients facing various neurological challenges.

Carlsmed is a medical technology company based in San Diego, California, specializing in spine surgery solutions. Founded in 2018, the company has developed the aprevo™ implant system, which is the first surgical implant designated as a breakthrough technology by the FDA. This innovative 3-D printed implant system offers personalized medicine benefits specifically for lumbar fusion surgery. Carlsmed employs machine learning technologies and analysis of prior outcomes data to enhance the treatment of complex adult spinal deformities, aiming to improve surgical outcomes and reduce healthcare costs associated with spine surgery. The company serves hospitals and surgeons nationwide, providing advanced solutions for adult spinal malalignment.

Route 92 Medical is a medical device company founded in 2015 and based in San Mateo, California. The company specializes in developing innovative solutions for stroke treatment, focusing on a stealthy catheter designed for acute ischemic stroke. Their technology includes a percutaneous catheter, a rapid aspiration thrombectomy system, and an intra-cerebral implant delivery mechanism. These advancements aim to assist healthcare professionals in effectively treating stroke patients and enhancing their recovery outcomes.

Carlsmed is a medical technology company based in San Diego, California, specializing in spine surgery solutions. Founded in 2018, the company has developed the aprevo™ implant system, which is the first surgical implant designated as a breakthrough technology by the FDA. This innovative 3-D printed implant system offers personalized medicine benefits specifically for lumbar fusion surgery. Carlsmed employs machine learning technologies and analysis of prior outcomes data to enhance the treatment of complex adult spinal deformities, aiming to improve surgical outcomes and reduce healthcare costs associated with spine surgery. The company serves hospitals and surgeons nationwide, providing advanced solutions for adult spinal malalignment.

Biorez, Inc. is a medical device company specializing in the development of bioresorbable scaffold implants aimed at regenerating functional tissue in vivo. Founded in 2008 and based in New Haven, Connecticut, Biorez offers innovative products such as an off-the-shelf implant for anterior cruciate ligament (ACL) reconstruction, which eliminates the need for harvesting donor tissue and serves as a superior alternative to cadaver-based materials. The company's technology utilizes a degradable polymer, specifically PLLA, to create implants that stabilize surgical repairs and facilitate the body's natural tissue regeneration, thereby enhancing musculoskeletal outcomes. Among its product lineup is the L-C Ligament® and the biorez GRAFT™, an FDA-cleared device designed for soft tissue augmentation of the rotator cuff. By leveraging this technology, Biorez aims to accelerate patient recovery and improve surgical outcomes in orthopedic procedures.

Biorez, Inc. is a medical device company specializing in the development of bioresorbable scaffold implants aimed at regenerating functional tissue in vivo. Founded in 2008 and based in New Haven, Connecticut, Biorez offers innovative products such as an off-the-shelf implant for anterior cruciate ligament (ACL) reconstruction, which eliminates the need for harvesting donor tissue and serves as a superior alternative to cadaver-based materials. The company's technology utilizes a degradable polymer, specifically PLLA, to create implants that stabilize surgical repairs and facilitate the body's natural tissue regeneration, thereby enhancing musculoskeletal outcomes. Among its product lineup is the L-C Ligament® and the biorez GRAFT™, an FDA-cleared device designed for soft tissue augmentation of the rotator cuff. By leveraging this technology, Biorez aims to accelerate patient recovery and improve surgical outcomes in orthopedic procedures.

Hinge Health, Inc. is a digital healthcare company focused on providing innovative solutions for individuals suffering from musculoskeletal disorders. Founded in 2015 and headquartered in San Francisco, California, the company develops wearable sensors, an application platform, and support services that facilitate the treatment of chronic back and joint pain. By combining advanced technology with access to a team of physical therapists, health coaches, and orthopedic surgeons, Hinge Health aims to make high-quality care more accessible and effective. Its offerings empower users to engage in personalized digital care, enabling them to manage their pain without relying on traditional methods such as surgery or opioid medications. With additional offices in Chicago, Minneapolis, Portland, and London, Hinge Health is committed to addressing the widespread issue of musculoskeletal pain and improving the well-being of its users.

Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, specializing in the treatment of carotid artery disease through its innovative transcarotid artery revascularization (TCAR) approach. Founded in 2007, the company develops and manufactures minimally invasive devices aimed at reducing the risk of stroke and improving patient outcomes. Its product portfolio includes the ENROUTE Transcarotid Neuroprotection System, which facilitates direct access to the common carotid artery while ensuring temporary blood flow reversal to protect the brain, and the ENROUTE Transcarotid Stent System, a self-expanding stent supported by clinical data on safety outcomes. Additionally, the ENHANCE Transcarotid Peripheral Access Kit and the ENROUTE 0.014 Guidewire are designed to aid in gaining access and delivering interventional devices effectively. Silk Road Medical aims to establish TCAR as the standard of care for carotid artery disease treatment.

Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating hemodialysis systems. The company has developed Tablo, a compact dialysis machine designed for use in both acute and chronic care settings. This system integrates essential features such as water purification, on-demand dialysate production, and advanced software capabilities, including wireless data connectivity and sensor-based automation. By simplifying the dialysis process, Tablo aims to reduce costs and enhance the experience for both patients and healthcare providers. Founded in 2003 and originally named Home Dialysis Plus, Ltd., Outset Medical rebranded in 2015 to reflect its commitment to transforming dialysis care.

Hinge Health, Inc. is a digital healthcare company focused on providing innovative solutions for individuals suffering from musculoskeletal disorders. Founded in 2015 and headquartered in San Francisco, California, the company develops wearable sensors, an application platform, and support services that facilitate the treatment of chronic back and joint pain. By combining advanced technology with access to a team of physical therapists, health coaches, and orthopedic surgeons, Hinge Health aims to make high-quality care more accessible and effective. Its offerings empower users to engage in personalized digital care, enabling them to manage their pain without relying on traditional methods such as surgery or opioid medications. With additional offices in Chicago, Minneapolis, Portland, and London, Hinge Health is committed to addressing the widespread issue of musculoskeletal pain and improving the well-being of its users.

Route 92 Medical is a medical device company founded in 2015 and based in San Mateo, California. The company specializes in developing innovative solutions for stroke treatment, focusing on a stealthy catheter designed for acute ischemic stroke. Their technology includes a percutaneous catheter, a rapid aspiration thrombectomy system, and an intra-cerebral implant delivery mechanism. These advancements aim to assist healthcare professionals in effectively treating stroke patients and enhancing their recovery outcomes.

Suture Concepts provides solutions for physicians who practice in a cost-conscious environment. They also provide solutions for securing soft tissue to other tissues, the bone, or medical devices.

Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, specializing in the treatment of carotid artery disease through its innovative transcarotid artery revascularization (TCAR) approach. Founded in 2007, the company develops and manufactures minimally invasive devices aimed at reducing the risk of stroke and improving patient outcomes. Its product portfolio includes the ENROUTE Transcarotid Neuroprotection System, which facilitates direct access to the common carotid artery while ensuring temporary blood flow reversal to protect the brain, and the ENROUTE Transcarotid Stent System, a self-expanding stent supported by clinical data on safety outcomes. Additionally, the ENHANCE Transcarotid Peripheral Access Kit and the ENROUTE 0.014 Guidewire are designed to aid in gaining access and delivering interventional devices effectively. Silk Road Medical aims to establish TCAR as the standard of care for carotid artery disease treatment.

Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating hemodialysis systems. The company has developed Tablo, a compact dialysis machine designed for use in both acute and chronic care settings. This system integrates essential features such as water purification, on-demand dialysate production, and advanced software capabilities, including wireless data connectivity and sensor-based automation. By simplifying the dialysis process, Tablo aims to reduce costs and enhance the experience for both patients and healthcare providers. Founded in 2003 and originally named Home Dialysis Plus, Ltd., Outset Medical rebranded in 2015 to reflect its commitment to transforming dialysis care.

Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating hemodialysis systems. The company has developed Tablo, a compact dialysis machine designed for use in both acute and chronic care settings. This system integrates essential features such as water purification, on-demand dialysate production, and advanced software capabilities, including wireless data connectivity and sensor-based automation. By simplifying the dialysis process, Tablo aims to reduce costs and enhance the experience for both patients and healthcare providers. Founded in 2003 and originally named Home Dialysis Plus, Ltd., Outset Medical rebranded in 2015 to reflect its commitment to transforming dialysis care.

Suture Concepts provides solutions for physicians who practice in a cost-conscious environment. They also provide solutions for securing soft tissue to other tissues, the bone, or medical devices.

Monteris Medical, Inc. is a medical device company that specializes in developing and marketing technologies for minimally invasive neurosurgery, particularly focused on the treatment of brain lesions. The company's flagship product, the NeuroBlate System, is a laser thermotherapy system designed for the volumetric ablation of pathological brain lesions, including both primary and metastatic tumors. This system utilizes magnetic resonance imaging (MRI) guidance and applies focused laser energy to effectively target and ablate tumors while minimizing damage to surrounding healthy tissue. Monteris Medical also offers various stereotactic anchoring devices for precise image-guided trajectory alignment, as well as stabilization systems for MRI-based procedures that require head fixation. Founded in 1999 and headquartered in Plymouth, Minnesota, the company serves neurosurgeons across the United States through a dedicated sales force. Monteris Medical was previously known as AutoLITT until rebranding in 2003.

Omada Health, Inc. is a digital healthcare company that specializes in developing online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, California, with an additional office in Atlanta, Georgia, Omada focuses on preventing conditions such as prediabetes, diabetes, hypertension, and heart disease. The company provides personalized digital health programs that cater to the unique needs of individuals, utilizing professional health coaching, connected health devices, and real-time data to facilitate meaningful health improvements. Omada is recognized as the largest provider of the National Diabetes Prevention Program, empowering individuals to engage actively in their health and achieve sustainable lifestyle changes. The platform also addresses behavioral health issues, including anxiety and depression, further supporting individuals in their overall wellness journey.

AtheroMed, Inc. is a medical device company based in Menlo Park, California, founded in 2006. The company specializes in developing catheter-based treatments for peripheral arterial disease (PAD). Its innovative system is designed to accommodate a range of vessel diameters, from small vessels at the ankle to larger vessels above the knee, thereby enhancing treatment options for patients suffering from this condition.

Omada Health, Inc. is a digital healthcare company that specializes in developing online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, California, with an additional office in Atlanta, Georgia, Omada focuses on preventing conditions such as prediabetes, diabetes, hypertension, and heart disease. The company provides personalized digital health programs that cater to the unique needs of individuals, utilizing professional health coaching, connected health devices, and real-time data to facilitate meaningful health improvements. Omada is recognized as the largest provider of the National Diabetes Prevention Program, empowering individuals to engage actively in their health and achieve sustainable lifestyle changes. The platform also addresses behavioral health issues, including anxiety and depression, further supporting individuals in their overall wellness journey.

Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, specializing in the treatment of carotid artery disease through its innovative transcarotid artery revascularization (TCAR) approach. Founded in 2007, the company develops and manufactures minimally invasive devices aimed at reducing the risk of stroke and improving patient outcomes. Its product portfolio includes the ENROUTE Transcarotid Neuroprotection System, which facilitates direct access to the common carotid artery while ensuring temporary blood flow reversal to protect the brain, and the ENROUTE Transcarotid Stent System, a self-expanding stent supported by clinical data on safety outcomes. Additionally, the ENHANCE Transcarotid Peripheral Access Kit and the ENROUTE 0.014 Guidewire are designed to aid in gaining access and delivering interventional devices effectively. Silk Road Medical aims to establish TCAR as the standard of care for carotid artery disease treatment.

AtheroMed, Inc. is a medical device company based in Menlo Park, California, founded in 2006. The company specializes in developing catheter-based treatments for peripheral arterial disease (PAD). Its innovative system is designed to accommodate a range of vessel diameters, from small vessels at the ankle to larger vessels above the knee, thereby enhancing treatment options for patients suffering from this condition.

Flexuspine is a spinal device company based in Pittsburgh, Pennsylvania, founded in 2003. It specializes in developing innovative spinal segment replacements designed as an alternative to traditional lumbar fusion surgeries. The company's primary offering is a functional spinal unit that combines an interbody disc component with a posterior dynamic resistance component, effectively restoring mobility to affected segments of the lumbar spine. This technology aims to enhance the overall functionality of the spine for patients following surgery, providing a comprehensive solution to spinal issues.

Suture Concepts provides solutions for physicians who practice in a cost-conscious environment. They also provide solutions for securing soft tissue to other tissues, the bone, or medical devices.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

ProteinSimple is a prominent company within the Protein Platforms division of Bio-Techne, specializing in innovative solutions for protein analysis. The company develops a comprehensive range of tools designed to assist life science researchers in addressing complex protein analysis challenges, thereby facilitating insights into proteins and their roles in diseases. Its product offerings include advanced immunoassay systems for quantifying protein expression and sophisticated systems for assessing the structure and purity of protein-based therapeutics. Additionally, ProteinSimple provides nano-proteomic analysis systems that enable researchers to measure phospho-protein signaling and activation in small biological samples, allowing for the quantification of phospho-protein isoforms in various cell types. Through these capabilities, ProteinSimple supports critical research in understanding cellular processes and monitoring drug actions in diverse biological contexts.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

ENTrigue Surgical specializes in the development and manufacturing of medical devices and instruments specifically for otolaryngology. The company focuses on innovating established techniques to create advanced tools and materials that enhance the efficiency, effectiveness, and comfort of sinus surgery for both surgeons and patients. By rethinking traditional practices, ENTrigue Surgical aims to improve surgical outcomes and patient experiences in the field of ear, nose, and throat medicine.

PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

ProteinSimple is a prominent company within the Protein Platforms division of Bio-Techne, specializing in innovative solutions for protein analysis. The company develops a comprehensive range of tools designed to assist life science researchers in addressing complex protein analysis challenges, thereby facilitating insights into proteins and their roles in diseases. Its product offerings include advanced immunoassay systems for quantifying protein expression and sophisticated systems for assessing the structure and purity of protein-based therapeutics. Additionally, ProteinSimple provides nano-proteomic analysis systems that enable researchers to measure phospho-protein signaling and activation in small biological samples, allowing for the quantification of phospho-protein isoforms in various cell types. Through these capabilities, ProteinSimple supports critical research in understanding cellular processes and monitoring drug actions in diverse biological contexts.

OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company based in Redwood City, California, specializing in the discovery and development of innovative therapeutics aimed at addressing the biological mechanisms that drive cancer growth, resistance, recurrence, and metastasis. The company is advancing several therapeutic candidates, including Navicixizumab, a bispecific monoclonal antibody targeting Delta-like ligand 4 and vascular endothelial growth factor, which has completed early-phase clinical trials for various solid tumors. Another key candidate, Etigilimab, is an anti-TIGIT monoclonal antibody currently undergoing Phase Ia/b clinical trials for advanced or metastatic solid tumors. OncoMed is also engaged in strategic partnerships aimed at the development of novel small molecule therapeutics and biologics targeting cancer stem cells and the Wnt signaling pathway. Founded in 2004, OncoMed Pharmaceuticals operates as a subsidiary of Mereo BioPharma Group plc.

ForteBio is a life science company focused on developing analytical systems for protein quantification and the characterization of protein-protein interactions. The company offers the Octet family of instruments, which facilitate real-time analysis of biomolecular interactions using micro-volume samples. These instruments provide essential data on affinity, kinetics, and concentration for proteins, peptides, DNA, RNA, and small molecules. Key products in the Octet line include the Octet RED, which is designed for quantitation and kinetics analysis while also enhancing the range and resolution for small molecule screening, as well as the Octet Q and QK models that perform similar analytical functions. By enabling rapid, real-time results, ForteBio's systems support scientists in their research endeavors.

Proteolix is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies targeting protein degradation pathways to address cancer and autoimmune diseases. The company’s lead product is a pioneering proteasome inhibitor, designed to evaluate safety and efficacy in treating multiple myeloma and various malignancies. In addition to this lead product, Proteolix is advancing a pipeline of novel proteasome inhibitors, which includes an oral formulation and a selective immunoproteasome inhibitor. These therapies aim to provide healthcare professionals with effective treatment options for specific hematologic cancers by inhibiting the cellular proteasome.

Meritage Pharma, Inc. is a company focused on developing prescription products for gastrointestinal and atopic diseases. Founded in 2008 and based in San Diego, California, it specializes in budesonide, a glucocorticoid steroid used in treatments for conditions such as pediatric asthma, allergic rhinitis, and Crohn's disease. The company's primary product candidate is an oral budesonide suspension aimed at treating adolescents and young adults with eosinophilic esophagitis, an allergic inflammation affecting the gastrointestinal tract. Through its innovative approaches, Meritage Pharma seeks to address significant medical needs in these areas.

Tepha, Inc. is a medical device company based in Lexington, Massachusetts, specializing in the development and manufacturing of medical device components utilizing proprietary biomaterial technology. Founded in 1998, the company focuses on absorbable biomaterials derived from polyhydroxyalkanoates (PHAs), engineered through recombinant DNA technology. Tepha's product offerings include monofilament sutures for soft tissue approximation, monofilament meshes for various surgical applications including hernia and prolapse repairs, and P4HB regenerative polymer scaffolds for treating stress urinary incontinence. Additionally, the company produces surgical films and composite meshes designed to enhance tissue support and minimize attachment. Tepha's innovative materials are characterized by their flexibility, elasticity, biocompatibility, and excellent tensile strength, addressing unmet needs across multiple medical fields.

BioSET, Inc. specializes in the research and development of synthetic bioactive peptides aimed at enhancing bone and soft tissue repair. The company offers a range of medical devices, including AMPLEX, an implantable combination device designed for surgical bone graft applications in spine fusion and other orthopedic procedures. BioSET's product portfolio also includes innovations for sports medicine, peptide signaling molecules, and various scaffold biomaterials, all intended for use in musculoskeletal applications such as trauma, fracture repair, and soft tissue treatments. Founded in 2001 and based in Rockville, Maryland, BioSET operates as a subsidiary of Ferring Pharmaceuticals Inc.

Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, specializing in the treatment of carotid artery disease through its innovative transcarotid artery revascularization (TCAR) approach. Founded in 2007, the company develops and manufactures minimally invasive devices aimed at reducing the risk of stroke and improving patient outcomes. Its product portfolio includes the ENROUTE Transcarotid Neuroprotection System, which facilitates direct access to the common carotid artery while ensuring temporary blood flow reversal to protect the brain, and the ENROUTE Transcarotid Stent System, a self-expanding stent supported by clinical data on safety outcomes. Additionally, the ENHANCE Transcarotid Peripheral Access Kit and the ENROUTE 0.014 Guidewire are designed to aid in gaining access and delivering interventional devices effectively. Silk Road Medical aims to establish TCAR as the standard of care for carotid artery disease treatment.

Bacchus Vascular, Inc. is a medical device company based in Santa Clara, California, specializing in the treatment of occlusive vascular disease. Founded in 1999, it develops innovative solutions for interventional radiologists and vascular surgeons in the United States. The company's flagship product, the TRELLIS-8 Peripheral Infusion System, is an isolated thrombolysis catheter designed to facilitate the targeted delivery of clot-dissolving drugs for the treatment of deep vein thrombosis and arterial occlusions. Additionally, Bacchus Vascular focuses on procedures for the percutaneous removal of blood clots from dialysis and peripheral grafts, as well as native arteries and veins, enhancing patient care in the field of vascular interventions.

PhyFlex Networks is a business services software and broadband access company that creates new business models for cable operators through its True Broadband solution. True Broadband includes a comprehensive software suite for the creation, provisioning, and management of end-to-end broadband services dynamically and on demand.

Elron Ventures is a venture capital firm based in Tel Aviv, Israel, founded in 1962. It specializes in seed and early-stage investments, focusing primarily on sectors such as enterprise software, cybersecurity, and medical technology. The firm is committed to transforming promising ideas into global industry leaders and has a notable history of successful investments and mergers and acquisitions. Elron Ventures has played a significant role in the Israeli innovation landscape, having been a founder and early investor in a variety of companies, including those in healthcare, defense, telecommunications, and medical devices. The firm's investment strategy emphasizes opportunities within Israel, reflecting its dedication to supporting local entrepreneurial talent.

Galil Medical Ltd. specializes in developing cryotherapy solutions aimed at treating various medical conditions across multiple specialties. Founded in 1996 and headquartered in Yokneam, Israel, with additional offices in Arden Hills, Minnesota, the company provides advanced cryosurgical systems that utilize compressed Argon gas to generate sub-zero temperatures for the cryosurgical ablation of both benign and cancerous tumors. Their product lineup includes the Visual-ICE system, which allows for precise control to protect critical anatomy, as well as the SeedNet and Presice systems designed for minimally invasive percutaneous procedures. Galil Medical's offerings extend to ultra-thin needles, thermal sensors, and other accessories that enhance the efficacy of their treatments. Their technologies are utilized in the management of conditions such as kidney, prostate, liver, lung, and breast cancers, among others. The company operates as a subsidiary of BTG plc, reflecting its integration into a broader healthcare framework.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.

Suture Concepts provides solutions for physicians who practice in a cost-conscious environment. They also provide solutions for securing soft tissue to other tissues, the bone, or medical devices.

PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

ProteinSimple is a prominent company within the Protein Platforms division of Bio-Techne, specializing in innovative solutions for protein analysis. The company develops a comprehensive range of tools designed to assist life science researchers in addressing complex protein analysis challenges, thereby facilitating insights into proteins and their roles in diseases. Its product offerings include advanced immunoassay systems for quantifying protein expression and sophisticated systems for assessing the structure and purity of protein-based therapeutics. Additionally, ProteinSimple provides nano-proteomic analysis systems that enable researchers to measure phospho-protein signaling and activation in small biological samples, allowing for the quantification of phospho-protein isoforms in various cell types. Through these capabilities, ProteinSimple supports critical research in understanding cellular processes and monitoring drug actions in diverse biological contexts.

ForteBio is a life science company focused on developing analytical systems for protein quantification and the characterization of protein-protein interactions. The company offers the Octet family of instruments, which facilitate real-time analysis of biomolecular interactions using micro-volume samples. These instruments provide essential data on affinity, kinetics, and concentration for proteins, peptides, DNA, RNA, and small molecules. Key products in the Octet line include the Octet RED, which is designed for quantitation and kinetics analysis while also enhancing the range and resolution for small molecule screening, as well as the Octet Q and QK models that perform similar analytical functions. By enabling rapid, real-time results, ForteBio's systems support scientists in their research endeavors.

PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company based in Redwood City, California, specializing in the discovery and development of innovative therapeutics aimed at addressing the biological mechanisms that drive cancer growth, resistance, recurrence, and metastasis. The company is advancing several therapeutic candidates, including Navicixizumab, a bispecific monoclonal antibody targeting Delta-like ligand 4 and vascular endothelial growth factor, which has completed early-phase clinical trials for various solid tumors. Another key candidate, Etigilimab, is an anti-TIGIT monoclonal antibody currently undergoing Phase Ia/b clinical trials for advanced or metastatic solid tumors. OncoMed is also engaged in strategic partnerships aimed at the development of novel small molecule therapeutics and biologics targeting cancer stem cells and the Wnt signaling pathway. Founded in 2004, OncoMed Pharmaceuticals operates as a subsidiary of Mereo BioPharma Group plc.

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

Velocimed was founded by a group of well known medical entrepreneurs. The company's founders envisioned a company that would become a global leader in the identification and development of innovative technologies with the power to improve the lives of patients whose clinical needs are not being met. Lead by a seasoned management team, Velocimed creates products internally and also looks externally for new technologies by partnering with physicians, inventors and institutions -- particularly those who may lack access to the necessary resources required for early development of new ideas. At Velocimed, they believe that they own a unique position in medical innovation and commercialization. Unlike small incubators, they have the expertise to commercialize viable technology. And unlike large companies, they have the ability to pinpoint opportunities faster and move more quickly.

Vascular Architects, Inc. specializes in designing, developing, manufacturing, and marketing medical devices aimed at treating vascular stenoses, occlusions, and non-vascular obstructions, with a particular focus on peripheral vascular disease. Founded in October 1997 by Dr. Thomas J. Fogarty, a distinguished surgeon and inventor, the company has established itself within the medical device industry by creating innovative surgical products for various markets, including cardiovascular and urology. Vascular Architects develops intraoperative vascular instruments such as Doppler probes and medical oxygen sensors, which are utilized across multiple surgical specialties. The company benefits from the expertise of a highly experienced management team and has engaged key opinion leaders from the interventional and vascular surgery communities to contribute to its Scientific Advisory Board.

BioSET, Inc. specializes in the research and development of synthetic bioactive peptides aimed at enhancing bone and soft tissue repair. The company offers a range of medical devices, including AMPLEX, an implantable combination device designed for surgical bone graft applications in spine fusion and other orthopedic procedures. BioSET's product portfolio also includes innovations for sports medicine, peptide signaling molecules, and various scaffold biomaterials, all intended for use in musculoskeletal applications such as trauma, fracture repair, and soft tissue treatments. Founded in 2001 and based in Rockville, Maryland, BioSET operates as a subsidiary of Ferring Pharmaceuticals Inc.

PhyFlex Networks is a business services software and broadband access company that creates new business models for cable operators through its True Broadband solution. True Broadband includes a comprehensive software suite for the creation, provisioning, and management of end-to-end broadband services dynamically and on demand.

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

OsteoBiologics is a biotechnology company. It engages in the development and manufacture of bio-absorbable polymeric scaffolds, films, and related instrumentations for the repair and replacement of bone, soft tissue, and articular cartilage. It provides ACTAEON, a tissue evaluation system, which determines the degree and scope of articular cartilage degeneration. It also manufactures custom parts. OsteoBiologics was founded in 1993 and is headquartered in San Antonio, Texas.

Bacchus Vascular, Inc. is a medical device company based in Santa Clara, California, specializing in the treatment of occlusive vascular disease. Founded in 1999, it develops innovative solutions for interventional radiologists and vascular surgeons in the United States. The company's flagship product, the TRELLIS-8 Peripheral Infusion System, is an isolated thrombolysis catheter designed to facilitate the targeted delivery of clot-dissolving drugs for the treatment of deep vein thrombosis and arterial occlusions. Additionally, Bacchus Vascular focuses on procedures for the percutaneous removal of blood clots from dialysis and peripheral grafts, as well as native arteries and veins, enhancing patient care in the field of vascular interventions.

Velocimed was founded by a group of well known medical entrepreneurs. The company's founders envisioned a company that would become a global leader in the identification and development of innovative technologies with the power to improve the lives of patients whose clinical needs are not being met. Lead by a seasoned management team, Velocimed creates products internally and also looks externally for new technologies by partnering with physicians, inventors and institutions -- particularly those who may lack access to the necessary resources required for early development of new ideas. At Velocimed, they believe that they own a unique position in medical innovation and commercialization. Unlike small incubators, they have the expertise to commercialize viable technology. And unlike large companies, they have the ability to pinpoint opportunities faster and move more quickly.

Vascular Architects, Inc. specializes in designing, developing, manufacturing, and marketing medical devices aimed at treating vascular stenoses, occlusions, and non-vascular obstructions, with a particular focus on peripheral vascular disease. Founded in October 1997 by Dr. Thomas J. Fogarty, a distinguished surgeon and inventor, the company has established itself within the medical device industry by creating innovative surgical products for various markets, including cardiovascular and urology. Vascular Architects develops intraoperative vascular instruments such as Doppler probes and medical oxygen sensors, which are utilized across multiple surgical specialties. The company benefits from the expertise of a highly experienced management team and has engaged key opinion leaders from the interventional and vascular surgery communities to contribute to its Scientific Advisory Board.

PhyFlex Networks is a business services software and broadband access company that creates new business models for cable operators through its True Broadband solution. True Broadband includes a comprehensive software suite for the creation, provisioning, and management of end-to-end broadband services dynamically and on demand.

BioSET, Inc. specializes in the research and development of synthetic bioactive peptides aimed at enhancing bone and soft tissue repair. The company offers a range of medical devices, including AMPLEX, an implantable combination device designed for surgical bone graft applications in spine fusion and other orthopedic procedures. BioSET's product portfolio also includes innovations for sports medicine, peptide signaling molecules, and various scaffold biomaterials, all intended for use in musculoskeletal applications such as trauma, fracture repair, and soft tissue treatments. Founded in 2001 and based in Rockville, Maryland, BioSET operates as a subsidiary of Ferring Pharmaceuticals Inc.

CardioThoracic Systems designs, develops, and manufactures surgical products and systems for minimally invasive cardiac surgery. The Company's current products are designed to enable the majority of cardiothoracic surgeons, using their existing skills coupled with company-sponsored training, to perform MICS on a beating heart. The OPCAB (Off Pump Coronary Artery Bypass) and MIDCAB (Minimally Invasive Direct Coronary Artery Bypass) procedures eliminate the need for a heart-lung machine, and recent studies indicate that the MICS procedures reduce the trauma, procedural costs and post-surgical complications associated with conventional coronary artery bypass graft (CABG) surgery while providing long-term procedural success rates comparable to CABG surgery. CardioThoracic Systems was founded in 1994 and is based in Cupertino, California. As of November 15, 1999, CardioThoracic Systems, Inc. was acquired by Guidant Corp.